Pharmacology letter accelerated communicationAffinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters
References (40)
- et al.
Eur. J. Pharmacol.
(1994) - et al.
Life Sci.
(1990) - et al.
Eur. J. Pharmacol.
(1993) Life Sci.
(1990)- et al.
Life Sci.
(1993) - et al.
Life Sci.
(1994) - et al.
Biochem. Pharmacol.
(1995) - et al.
Eur. J. Pharmacol.
(1991) - et al.
J. Neurochem.
(1985) - et al.
Arch. Gen. Psychiat.
(1987)
Science
J. Nucl. Med.
Eur. J. Pharmacol.
J. Nucl. Med.
Synapse
Arch. Gen. Psychiat.
Helv. Chim. Acta
J. Med. Chem.
J. Pharmacol. Exp. Ther.
Cited by (185)
Effects of methylphenidate after a long period of discontinuation include changes in exploratory behavior and increases brain activities of Na<sup>+</sup>,K<sup>+</sup>-ATPase and acetylcholinesterase
2022, Neurobiology of Learning and MemoryCitation Excerpt :Its neuropharmacological profile is similar to that of cocaine or amphetamine, which it is thought to indirectly increase dopamine (DA) levels by blocking the dopamine active transporter (DAT) (Challman & Lipsky, 2000; Schmeichel & Berridge, 2013). Moreover, MPH has an affinity for blocking norepinephrine (NE) and serotonin transporters, although less than for DA (Gatley, SJ; Pan, D; Chen, R; Chaturvedi, G; Ding, 1996; Hannestad et al., 2010; Kuczenski & Segal, 1997). Treatment with MPH is usually well tolerated and its efficacy in reducing symptoms of ADHD is consistently reported (Oh et al., 2018; Sudnawa et al., 2018), but due to the large increase in rates of MPH prescriptions over the last years and its pharmacological profile and ease of access, researchers have also been quite concerned about the increased incidence of MPH misuse (Johnston, LD; O’Malley, PM; Bachman, JG; Schullenberg, 2011a, 2011b).
Role of pharmacokinetic and pharmacodynamic parameters in neuroadaptations induced by drugs of abuse, with a focus on opioids and psychostimulants
2019, Neuroscience and Biobehavioral Reviews